drugset / Trial / NCT02262143
Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Efficacy and safety of combination therapy of rosuvastatin and fenofibrate versus rosuvastatin monotherapy in mixed dyslipidemia patients: A randomized, multi-center, double-blind, phase 3 study
Timeline
- Start
- 2014-11
- Primary completion
- 2016-10
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fenofibrate | Small molecule | 160 mg | Oral |
| Background | Rosuvastatin | Small molecule | 10 mg | Oral |